

PERSONAL INFORMATION

Elisa Bianchi



Work address:

Centre for Regenerative Medicine, University of Modena and Reggio Emilia,
Via G. Gottardi 100, 41125 Modena, Italy

 +39 059 2058809

 elisa.bianchi@unimore.it

ORCID: <http://orcid.org/0000-0002-6110-5944>

SCOPUS: <https://www.scopus.com/authid/detail.uri?authorId=56639929100>

CURRENT POSITION

Associate Professor in Experimental Biology .

Department of Life Sciences, University of Modena and Reggio Emilia, Italy.

WORK EXPERIENCE

- | | |
|-----------------------|--|
| 01/12/2018–01/12/2021 | Researcher position (RTD, art.24 comma 3 lett b, Legge 30.12.2010, n.240) for the disciplinary area BIOS-10/A– Experimental Biology
Department of Life Sciences, University of Modena and Reggio Emilia, Italy. |
| 15/09/2015–30/11/2018 | Post-doctoral Senior Research Fellow. Title: Identification of the molecular mechanisms underlying stemness, differentiation and tumorigenesis/oncogenesis in epithelial and hematopoietic stem cells through an integrated biomolecular approach.
Department of Life Sciences, University of Modena and Reggio Emilia, Italy. |
| 10/09/2012–09/09/2015 | Researcher position (RTD, art.24 comma 3 lett a, Legge 30.12.2010, n.240) for the project “Dry eye syndromes treatment with regenerative medicine: molecular and cellular biology approaches for the characterization of mechanisms involved in the generation of unicellular mucin glands from conjunctival stem cells”.
Centre for Regenerative Medicine, University of Modena and Reggio Emilia, Italy. |
| 01/01/2008–09/09/2012 | Post-doctoral Research Fellow (Assegno di Ricerca). Title: Study of normal and leukemic Hematopoietic Stem Cells.
Biomedical Sciences Department, University of Modena and Reggio Emilia, Italy. |
| 01/01/2006–31/12/2007 | Research and Advanced Training Fellowship.
University of Ferrara, Italy. |

EDUCATION AND TRAINING

- | | |
|-----------|---|
| 14/2/2008 | Ph.D. in Biotechnology and Molecular Medicine, University of Modena and Reggio Emilia, Italy. Thesis: "c-Myb silencing in human hematopoietic stem/progenitor cells induces the macrophage and megakaryocyte differentiation".
Supervisor: Prof. Rossella Manfredini. |
| 15/9/2004 | Medical Biotechnology degree (ante DM 509/99). Final mark: 110/110 with honors. Experimental thesis: “Comparative analysis of the molecular phenotype of normal and Chronic Myeloid Leukemia hematopoietic stem cell subpopulations”.
University of Modena and Reggio Emilia, Italy. Supervisor: Prof. Rossella Manfredini. |

Functional characterization of transcriptional and post-transcriptional control of normal hematopoiesis:

- Study of the role of the transcription factors MYB and MAF in human CD34+ hematopoietic stem/progenitor cells commitment and functional characterization of the MYB/has-miR-486-3p/MAF axis in human CD34+ stem/progenitor cells commitment (*Bianchi, Blood, 2010; Bianchi, Cell Death Differ, 2015; Ruberti & Bianchi, Leukemia, 2018*).
- Functional characterization of the role of miRNAs (e.g. hsa-miR-34a-5p e hsa-miR-486-3p) in human CD34+ stem/progenitor cells commitment (*Bianchi, Cell Death Differ, 2015; Bianchi, IJMS, 2017; Tenedini, Cell Death Disease, 2010*).
- Study of the role of CD34 antigen during myeloid differentiation (*Salati, Stem Cells, 2008*).
- Functional and molecular characterization of hematopoietic progenitor cells and terminally differentiated myeloid cells (*Salati & Bianchi, Haematologica, 2007; Tenedini, Cell Death Disease, 2010*).

Functional characterization of the molecular mechanisms underlying neoplastic hematopoiesis:

- Functional characterization of the MAF/SPP1 axis in the pathogenesis of Primary Myelofibrosis (*Bianchi, Leukemia, 2023; Ruberti & Bianchi, Leukemia, 2018*).
- Characterization of the genomic lesions underlying the pathogenesis of Myeloproliferative Neoplasms (*Parenti, NPJ Precis Oncol. 2021*).
- Functional characterization of the role of genes and miRNAs in Primary Myelofibrosis patients (*Ruberti & Bianchi, Leukemia, 2018; Bianchi, IJMS, 2017; Norfo, Blood, 2014; Rontautoli, Oncotarget, 2017*).
- Gene, miRNA and long non-coding RNA expression analysis in hematopoietic stem/progenitor cells, granulocytes and plasma from Primary Myelofibrosis patients (*Fantini S, Cancers, 2021; Rontautoli S, Blood Adv, 2021; Norfo, Blood, 2014*).
- Molecular and functional analysis of stem cells-enriched subpopulations from Chronic Myelogenous Leukemia patients (*Lemoli, Blood, 2009*).

TEACHING ACTIVITY

Academic Year 2025/2026

Teaching activity (112 hours), course: "Cellular Biology and laboratory", Biotechnologies School, University of Modena & Reggio Emilia.

Teaching activity (12 hours), course: "Molecular Bases of Life", Nursing School, University of Modena & Reggio Emilia

Academic Year 2024/2025

Teaching activity (112 hours), course: "Cellular Biology and laboratory", Biotechnologies School, University of Modena & Reggio Emilia.

Teaching activity (12 hours), course: "Molecular Bases of Life", Nursing School, University of Modena & Reggio Emilia

Academic Year 2023/2024

Teaching activity (112 hours), course: "Cellular Biology and laboratory", Biotechnologies School, University of Modena & Reggio Emilia.

Teaching activity (12 hours), course: "Molecular Bases of Life", Nursing School, University of Modena & Reggio Emilia

Academic Year 2022/2023

Teaching activity (112 hours), course: "Cellular Biology and laboratory",

Biotechnologies School, University of Modena & Reggio Emilia.

Teaching activity (20 hours), course: "Foundations of Biological Sciences", Health Care School, University of Modena & Reggio Emilia.

Teaching activity (12 hours), course: "Molecular Bases of Life", Nursing School, University of Modena & Reggio Emilia

Academic Year 2021/2022

Teaching activity (64 hours), course: "Cellular Biology and laboratory", Biotechnologies School, University of Modena & Reggio Emilia.

Teaching activity (16 hours), course: "Animal Models for the study of diseases", Medical Biotechnologies School, University of Modena & Reggio Emilia

Academic Year 2020/2021

Teaching activity (16 hours), course: "Animal Models for the study of diseases", Medical Biotechnologies School, University of Modena & Reggio Emilia

Teaching activity (56 hours), course: "Cellular Biology and laboratory", Biotechnologies School, University of Modena & Reggio Emilia.

Academic Year 2019/2020

Teaching activity (21 hours), course: "Cellular Biology and laboratory", Biotechnologies School, University of Modena & Reggio Emilia.

Academic Year 2018/2019

Teaching activity (32 hours), course: "Cellular And Biomolecular Technologies", Biotechnologies School, University of Modena & Reggio Emilia.

Academic Year 2017/2018

Teaching activity (10 hours), course: "Biology and Genetics", School of Medicine, University of Modena & Reggio Emilia.

Academic Year 2017/2018

Teaching activity (15 hours), course: "Animal Models for the study of diseases", Medical Biotechnologies School, University of Modena & Reggio Emilia

Academic Year 2016/2017

Teaching activity (10 hours), course: "Biology and Genetics", School of Medicine, University of Modena & Reggio Emilia.

Academic Year 2016/2017

Teaching activity (15 hours), course: "Animal Models for the study of diseases", Medical Biotechnologies School, University of Modena & Reggio Emilia

Academic Year 2015/2016

Teaching activity (10 hours), course: "Biology and Genetics", School of Medicine, University of Modena & Reggio Emilia.

Academic Year 2015/2016

Teaching activity (15 hours), course: "Animal Models for the study of diseases", Medical Biotechnologies School, University of Modena & Reggio Emilia

Academic Year 2014/2015

Teaching activity (10 hours), course: "Biology and Genetics", School of Medicine, University of Modena & Reggio Emilia.

Academic Year 2013/2014

Teaching activity (10 hours), course: "Biology and Genetics", School of Medicine, University of Modena & Reggio Emilia.

Academic Year 2013/2014

Teaching activity (15 hours), course: "Animal Models for the study of diseases", Medical and Pharmacological Biotechnologies School, University of Modena & Reggio Emilia

Academic Year 2012/2013

Teaching activity (15 hours), course: "Animal Models for the study of diseases", Medical and Pharmacological Biotechnologies School.

Academic Year 2011/2012

Teaching activity (20 hours), course: "Animal Models for the study of diseases", Medical and Pharmacological Biotechnologies School.

COMPETITIVE RESEARCH GRANTS

- 2023 **PRIN (Programmi Di Ricerca Scientifica Di Rilevante Interesse Nazionale) 2022** under 40 (DD n.104 del 2 febbraio 2022) founded by the Italian Ministry for University and Research (MIUR). Project title: "The transcription factor MAF and Toll-like Receptors as key players in the inflammatory and pro-fibrotic landscape of myelofibrosis" (€ 230679)
- 2021 **AIRC (Italian Association for Cancer Research) "My First AIRC Grant" (MFAG)** "Dissecting the role of the proto-oncogene MAF and the pathways that fuel fibrosis and inflammation in myelofibrosis" (€ 499997.60).
- 2012 **FIRB (Fondo per gli Investimenti della Ricerca di Base) "Futuro in Ricerca 2010"** grant founded by the **Italian Ministry for University and Research (MIUR)** for the research project "Dry eye syndromes treatment with regenerative medicine: molecular and cellular biology approaches for the characterization of mechanisms involved in the generation of unicellular mucin glands from conjunctival stem cells" (€ 348492).

PUBLICATIONS

1. Combined MEK and JAK inhibition reduces osteopontin plasma level and bone marrow fibrosis in a myelofibrosis mouse model. Tavernari L, Bertesi M, Neroni A, Papa E, Rontautoli S, Bianchi E, Mirabile M, Norfo R, Parenti S, Tombari C, Carretta C, Malerba M, Fabbiani L, Guglielmelli P, Losi L, Tagliafico E, Vannucchi AM, Manfredini R; MYNERVA (MYeloid NEoplasms Research Venture AIRC) investigators. Blood Cancer J. 2025 Nov 15;15(1):197. doi: 10.1038/s41408-025-01409-3.
2. Mirabile M, Tombari C, Neroni A, Tavernari L, Norfo R, Bianchi E, Maccaferri M, Mora B, Parenti S, Carretta C, Bertesi M, Malerba M, Papa E, Fabbiani L, Bartalucci N, Guglielmelli P, Potenza L, Losi L, Passamonti F, Tagliafico E, Luppi M, Rontautoli S, Vannucchi AM, Manfredini R; MYNERVA (Myeloid NEoplasms Research Venture AIRC) investigators. CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis. J Cell Mol Med. 2025 Jul;29(14):e70720. doi: 10.1111/jcmm.70720.
3. Carretta C, Parenti S, Bertesi M, Rontautoli S, Badii F, Tavernari L, Genovese E, Malerba M, Papa E, Sperduti S, Enzo E, Mirabile M, Pedrazzi F, Neroni A, Tombari C, Mora B, Maffioli M, Mondini M, Brociner M, Maccaferri M, Tenedini E, Martinelli S, Bartalucci N, Bianchi E, Casarini L, Potenza L, Luppi M, Tagliafico E, Guglielmelli P, Simoni M,

- Passamonti F, Norfo R, Vannucchi AM, Manfredini R; MYNERVA (Myeloid NEoplasms Research Venture AIRC). Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms. *Leukemia*. 2024 Oct;38(10):2171-2182. doi: 10.1038/s41375-024-02373-w. Epub 2024 Aug 23.
4. Tavernari L, Rontautoli S, Norfo R, Mirabile M, Maccaferri M, Mora B, Genovese E, Parenti S, Carretta C, Bianchi E, Bertesi M, Pedrazzi F, Tenedini E, Martinelli S, Boichicchio MT, Guglielmelli P, Potenza L, Lucchesi A, Passamonti F, Tagliafico E, Luppi M, Vannucchi AM, Manfredini R; MYNERVA (Myeloid NEoplasms Research Venture AIRC) investigators. Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts. *Am J Hematol*. 2024 Oct;99(10):1939-1950. doi: 10.1002/ajh.27428. Epub 2024 Jul 2.
 5. Eustachio Attico, Giulia Galaverni, Andrea Torello, Elisa Bianchi, Susanna Bonacorsi, Lorena Losi, Rossella Manfredini, Alessandro Lambiase, Paolo Rama and Graziella Pellegrini. Comparison between Cultivated Oral Mucosa and Ocular Surface Epithelia for COMET Patients Follow-Up. *Int. J. Mol. Sci.* 2023, 24(14), 11522; <https://doi.org/10.3390/ijms241411522>. I.F (JCR) 2022: 5.6
 6. Bianchi E, Rontautoli S, Tavernari L, Mirabile M, Pedrazzi F, Genovese E, Sartini S, Dall'Ora M, Grisendi G, Fabbiani L, Maccaferri M, Carretta C, Parenti S, Fantini S, Bartalucci N, Calabresi L, Balliu M, Guglielmelli P, Potenza L, Tagliafico E, Losi L, Dominici M, Luppi M, Vannucchi AM, Manfredini R. Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model. *Leukemia*. 2023 Mar 16. doi: 10.1038/s41375-023-01867-3. Online ahead of print. **ISSN 0887-6924**. [§]E.B. and R.M. are co-corresponding authors. I.F (JCR) 2021: 12.897
 7. Attico E, Galaverni G, Bianchi E, Losi L, Manfredini R, Lambiase A, Rama P, Pellegrini G. SOX2 Is a Univocal Marker for Human Oral Mucosa Epithelium Useful in Post-COMET Patient Characterization. *Int J Mol Sci*. 2022 May 21;23(10):5785. doi: 10.3390/ijms23105785. **ISSN 1422-0067 (Online)**. I.F (JCR) 2022: 5.6
 8. Elena Genovese, Margherita Mirabile, Sebastiano Rontautoli, Stefano Sartini, Sebastian Fantini, Lara Tavernari, Monica Maccaferri, Paola Guglielmelli, Elisa Bianchi, Sandra Parenti, Chiara Carretta, Selene Mallia, Sara Castellano, Corrado Colasante, Manjola Balliu, Niccolò Bartalucci, Raffaele Palmieri, Tiziana Ottone, Barbara Mora, Leonardo Potenza, Francesco Passamonti, Maria Teresa Voso, Mario Luppi, Alessandro Maria Vannucchi, Enrico Tagliafico, Rossella Manfredini on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC). The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. *Antioxidants* 2022, 11(1), 113; <https://doi.org/10.3390/antiox11010113>. **ISSN: 2076-3921**. I.F (JCR) 2022: 7
 9. Fantini S, Rontautoli S, Sartini S, Mirabile M, Bianchi E, Badii F, Maccaferri M, Guglielmelli P, Ottone T, Palmieri R, Genovese E, Carretta C, Parenti S, Mallia S, Tavernari L, Salvadori C, Gesullo F, Maccari C, Zizza M, Grande A, Salmoiraghi S, Mora B, Potenza L, Rosti V, Passamonti F, Rambaldi A, Voso MT, Mecucci C, Tagliafico E, Luppi M, Vannucchi AM, Manfredini R. Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. *Cancers (Basel)*. 2021 Sep 22;13(19):4744. doi: 10.3390/cancers13194744. **ISSN: 2072-6694**. I.F (JCR) 2022: 5.2
 10. S. Rontautoli, S. Castellano, P. Guglielmelli, R. Zini, E. **Bianchi**, E. Genovese, C. Carretta, S. Parenti, S. Fantini, S. Mallia, L. Tavernari, S. Sartini, M. Mirabile, C. Mannarelli, F. Gesullo, A. Pacilli, D. Pietra, E. Rumi, S. Salmoiraghi, B. Mora, L. Villani, A. Grilli, V. Rosti, G. Barosi, F. Passamonti, A. Rambaldi, L. Malcovati, M. Cazzola, S. Biciato, E. Tagliafico, A.M. Vannucchi and R. Manfredini, on behalf of

Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators. Gene expression profile correlates with molecular and clinical features in myelofibrosis patients. *Blood Adv* (2021) 5 (5): 1452–1462. doi: 10.1182/bloodadvances.2020003614. **ISSN 2473-9537 (Online)**. I.F (JCR) 2022: 7.5

11. Parenti S, Rontauoli S, Carretta C, Mallia S, Genovese E, Chiereghin C, Peano C, Tavernari L, **Bianchi E**, Fantini S, Sartini S, Romano O, Bicciato S, Tagliafico E, Della Porta M, Manfredini R. Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis. *NPJ Precis Oncol*. 2021 Feb 4;5(1):4. doi: 10.1038/s41698-021-00144-9. **ISSN 2397-768X (Online)**. I.F (JCR) 2022: 7.9
12. Carretta C, Mallia S, Genovese E, Parenti S, Rontauoli S, **Bianchi E**, Fantini S, Sartini S, Tavernari L, Tagliafico E, Manfredini R. Genomic Analysis of Hematopoietic Stem Cell at the Single-Cell Level: Optimization of Cell Fixation and Whole Genome Amplification (WGA) Protocol. *Int J Mol Sci*. 2020 Oct 6;21(19):E7366. doi: 10.3390/ijms21197366. **ISSN 1422-0067 (Online)**. I.F (JCR) 2022: 5.6
13. Salati S, Genovese E, Carretta C, Zini R, Bartalucci N, Prudente Z, Pennucci V, Ruberti S, Rossi C, Rontauoli S, Enzo E, Calabresi L, Balliu M, Mannarelli C, **Bianchi E**, Guglielmelli P, Tagliafico E, Vannucchi AM, Manfredini R. Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. *Sci Rep*. 2019 Jul 22;9(1):10558. doi: 10.1038/s41598-019-46843-z. Springer Nature. **ISSN 2045-2322 (online)**. I.F (JCR) 2022: 4.6
14. Sceberas V, Attico E, **Bianchi E**, Galaverni G, Melonari M, Corradini F, Fantacci M, Ribbene A, Losi L, Balò S, Lazzeri M, Trombetta C, Rizzo M, Manfredini R, Barbagli G, Pellegrini G. Preclinical study for treatment of hypospadias by advanced therapy medicinal products. *World J Urol*. 2020, 38(9). doi: 10.1007/s00345-019-02864-x. Published by Springer Nature Switzerland AG. Part of Springer Nature. **ISSN: 0724-4983 (Print) 1433-8726 (Online)**. I.F (JCR) 2022: 3.4
15. Rossi C, Zini R, Rontauoli S, Ruberti S, Prudente Z, Barbieri G, **Bianchi E**, Salati S, Genovese E, Bartalucci N, Guglielmelli P, Tagliafico E, Rosti V, Barosi G, Vannucchi AM, Manfredini R. Role of TGF- β 1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis. *Mol Oncol*. 2018 Sep 27. Published by FEBS Press and John Wiley & Sons Ltd. Online **ISSN: 1878-0261**. doi: 10.1002/1878-0261.12387. I.F (JCR) 2022: 6.6
16. Samantha Ruberti*, **Elisa Bianchi***[§], Paola Guglielmelli, Sebastiano Rontauoli, Greta Barbieri, Lara Tavernari, Tiziana Fanelli, Ruggiero Norfo, Valentina Pennucci, Giuditta Corbizi Fattori, Carmela Mannarelli, Niccolò Bartalucci, Barbara Mora, Lorenzo Elli, Maria Antonietta Avanzini, Chiara Rossi, Silvia Salmoiraghi, Roberta Zini, Simona Salati, Zelia Prudente, Vittorio Rosti, Francesco Passamonti, Alessandro Rambaldi, Sergio Ferrari, Enrico Tagliafico, Alessandro Vannucchi, and Rossella Manfredini[§]. "Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients". *Leukemia*. 2018 Feb;32(2):438-449. *Macmillan Publishers, part of Springer Nature, London, UK*. **ISSN 0887-6924**. doi: 10.1038/leu.2017.220. *E.B. and S.R. are co-first authors. [§] E.B. and R.M. are co-corresponding authors. I.F (JCR) 2022: 11.4
17. Salati S., Prudente Z., Genovese E., Pennucci V., Rontauoli S., Bartalucci N., Mannarelli C., Ruberti S., Zini R., Rossi C., **Bianchi E**, Guglielmelli P., Tagliafico E., Vannucchi AM. and Manfredini R. Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation. *Stem Cells and Development*, 27(4):225-236, 2017. Mary Ann Liebert, Inc. publishers, New Rochelle, New York, USA. **ISSN: 1547-3287**. DOI: 10.1089/scd.2017.0137. I.F (JCR) 2022: 4
18. Zini R., Guglielmelli P., Pietra D., Rumi E., Rossi C., Rontauoli S., Genovese E., Fanelli T., Calabresi L., **Bianchi E**, Salati S., Cazzola M., Tagliafico E., Vannucchi A.M.,

Manfredini R. "CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles". *Blood Cancer Journal* 2017 Dec 8;7(12):638. *Macmillan Publishers, part of Springer Nature, London, UK. ISSN 2044-5385.* doi: 10.1038/s41408-017-0010-2. I.F (JCR) 2022: 12.8

19. Catani L, Sollazzo D, **Bianchi E**, Ciciarello M, Antoniani C, Foscoli L, Caraceni P, Giannone FA, Baldassarre M, Giordano R, Montemurro T, Montelatici E, D'Errico A, Andreone P, Giudice V, Curti A, Manfredini R, Lemoli RM. Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells. *Cytotherapy*. 2017 Dec;19(12):1447-1461. *Elsevier Inc. Chicago, Illinois, USA. ISSN: 1465-3249.* doi: 10.1016/j.jcyt.2017.08.001. I.F (JCR) 2021: I.F (JCR) 2022: 4.5
20. **Bianchi E***, Ruberti S, Rontauoli S, Guglielmelli P, Salati S, Rossi C, Zini R, Tagliafico E, Vannucchi AM, Manfredini R*. "Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis". *Int J Mol Sci*. 2017 Jan 13;18(1). pii: E145. *MDPI, Basel, Switzerland. ISSN 1422-0067.* doi: 10.3390/ijms18010145. *Bianchi E and Manfredini R are co-corresponding authors. I.F (JCR) 2022: 5.6
21. Rontauoli S, Norfo R, Pennucci V, Zini R, Ruberti S, **Bianchi E**, Salati S, Prudente Z, Rossi C, Rosti V, Guglielmelli P, Barosi G, Vannucchi A, Tagliafico E, Manfredini R. "miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6". *Oncotarget*. 2017 Mar 28;8(13):21380-21397. *Impact Journals LLC, Orchard Park, NY, USA. ISSN: 1949-2553.* doi: 10.18632/oncotarget.15226.
22. Salati S., Salvestrini V., Carretta C., Rontauoli S., Zini R., Rossi C., Ruberti S., **Bianchi E.**, Pennucci V., Curti A., Lemoli R.M., Manfredini R. "Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells". *Oncotarget*. 2017 Jul 25;8(30):49451-49469. *Impact Journals LLC, Orchard Park, NY, USA. ISSN: 1949-2553.* doi: 10.18632/oncotarget.17706.
23. Zini R., Rossi C., Norfo R., Pennucci V., Barbieri G., Ruberti S., Rontauoli S., Salati S., **Bianchi E.**, and Manfredini R. "MiR-382-5p controls hematopoietic stem cell differentiation through the downregulation of MXD1". *Stem Cells Dev*. 2016 Oct 1;25(19):1433-43. Mary Ann Liebert, Inc. publishers, New Rochelle, New York, USA. ISSN: 1547-3287. doi: 10.1089/scd.2016.0150. I.F (JCR) 2022: 4
24. Tomasella A, Picco R, Ciotti S, Sgorbissa A, **Bianchi E**, Manfredini R, Benedetti F, Trimarco V, Frezzato F, Trentin L, Semenzato G, Delia D, Brancolini C. The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells. *Oncotarget*. 2016 Jul 19;7(29):45429-45443. *Impact Journals LLC, Orchard Park, NY, USA. ISSN: 1949-2553.* doi: 10.18632/oncotarget.9742.
25. **Bianchi E**, Norfo R, Pennucci V, Zini R, Manfredini R. Genomic landscape of megakaryopoiesis and platelet function defects. *Blood*. 2016 Mar 10;127(10):1249-59. *The American Society of Hematology, Washington, DC, USA. ISSN 0006-4971.* doi: 10.1182/blood-2015-07-607952. I.F (JCR) 2022: 20.3
26. Salati S, Zini R, Nuzzo S, Guglielmelli P, Pennucci V, Prudente Z, Ruberti S, Rontauoli S, Norfo R, **Bianchi E**, Bogani C, Rotunno G, Fanelli T, Mannarelli C, Rosti V, Salmoiraghi S, Pietra D, Ferrari S, Barosi G, Rambaldi A, Cazzola M, Biciato S, Tagliafico E, Vannucchi AM, Manfredini R; AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) investigators. Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis. *Int J Cancer*. 2016 Apr 1;138(7):1657-69. *UICC, Geneva, Switzerland. ISSN 1097-0215.* doi: 10.1002/ijc.29920. I.F (JCR) 2022: 6.4

27. **Bianchi E**, Bulgarelli J, Ruberti S, Rontautoli S, Sacchi G, Norfo R, Pennucci V, Zini R, Salati S, Prudente Z, Ferrari S, Manfredini R. MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF. *Cell Death Differ.* 2015 Dec;22(12):1906-21. *Macmillan Publishers, Part of Springer Nature, London UK. ISSN 1350-9047.* doi: 10.1038/cdd.2015.30 I.F (JCR) 2022: 12.4
28. Tenedini E, Bernardis I, Artusi V, Artuso L, Roncaglia E, Guglielmelli P, Pieri L, Bogani C, Biamonte F, Rotunno G, Mannarelli C, **Bianchi E**, Pancrazzi A, Fanelli T, Malagoli Tagliazucchi G, Ferrari S, Manfredini R, Vannucchi AM, Tagliafico E. Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. *Leukemia.* 2014 May;28(5):1052-9. *Macmillan Publishers Limited, part of Springer Nature, London, UK. ISSN 0887-6924.* doi: 10.1038/leu.2013.302. I.F (JCR) 2022: 11.4
29. Norfo R. °, Zini R. °, Pennucci V. °, **Bianchi E.**, Salati S., Guglielmelli P., Bogani C., Fanelli T., Mannarelli C., Rosti V., Pietra D., Salmoiraghi S., Bisognin A., Ruberti S., Rontautoli S., Sacchi G., Prudente Z., Barosi G., Cazzola M., Rambaldi A., Bortoluzzi S., Ferrari S., Tagliafico E., Vannucchi A.M., and Manfredini R. " miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis". *Blood.* 2014 Sep 25;124(13):e21-32. *The American Society of Hematology, Washington, DC, USA. ISSN 0006-4971.* doi: 10.1182/blood-2013-12-544197. I.F (JCR) 2022: 20.3
30. Pennucci V., Zini R., Norfo R., Guglielmelli P., **Bianchi E.**, Salati S., Sacchi G., Prudente Z., Tenedini E., Ruberti S., Paoli C., Fanelli T., Mannarelli C., Tagliafico E., Ferrari S., Vannucchi A.M., Manfredini R. "Abnormal Expression of WT1-as, MEG3 and ANRIL Long Non-Coding RNAs in CD34+ Cells from Patients with Primary Myelofibrosis and Its Clinical Correlates". *Leuk Lymphoma.* 2015 Feb;56(2):492-6. *Informa UK, Ltd., London, UK. ISSN: 1042-8194.* doi: 10.3109/10428194.2014.910661. I.F (JCR) 2022: 2.6
31. Salati S., Lisignoli G., Manferdini C., Pennucci V., Zini R., **Bianchi E.**, Norfo R., Facchini A., Ferrari S., and Manfredini R. "Co-culture of Human Hematopoietic Stem Cells with Osteoblasts Affects Mono/macrophage versus Erythroid Lineage Choice". *PLoS One.* 2013;8(1):e53496. *PLOS, San Francisco, California, USA. ISSN 1932-6203.* doi: 10.1371/journal.pone.0053496. I.F (JCR) 2022: 3.7
32. Zini R., Norfo R., Ferrari F., **Bianchi E.**, Salati S., Carboni C., Ceccherelli G.B., Tagliafico E., Ferrari S., and Manfredini R. "Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GF1B and MLLT3 expression.". *Exp Hematol.* 2012 Dec;40(12):1043-1054.e6. *Elsevier Inc. Chicago, Illinois, USA. ISSN 0301-472X.* doi: 10.1016/j.exphem.2012.08.003. I.F (JCR) 2022: 2.6
33. Salvestrini V., Zini R., Rossi L., Gulinelli S., Manfredini R., **Bianchi E.**, Piacibello W., Caione L., Migliardi G., Ricciardi M., Tafuri A., Romano M., Salati S., Di Virgilio F., Ferrari S., Baccarani M., Ferrari D., and Lemoli R.M. "Purinergic signaling inhibits human Acute Myeloblastic Leukemia cell proliferation, migration and engraftment in Immunodeficient mice". *Blood.* 2012 Jan 5;119(1):217-26. *The American Society of Hematology, Washington, DC, USA. ISSN 0006-4971.* doi: 10.1182/blood-2011-07-370775. I.F (JCR) 2022: 20.3
34. **Bianchi E**, Zini R, Salati S, Tenedini E, Norfo R, Tagliafico E, Manfredini R, Ferrari S. c-Myb supports erythropoiesis through the transactivation of KLF1 and LMO2 expression. *Blood.* 2010 Nov 25;116(22):e99-110. *The American Society of Hematology, Washington, DC, USA. ISSN 0006-4971.* doi: 10.1182/blood-2009-08-238311. I.F (JCR) 2022: 20.3
35. Elena Tenedini, Enrica Roncaglia, Francesco Ferrari, Claudia Orlandi, **Elisa Bianchi**, Silvio Bicciato, Enrico Tagliafico and Sergio Ferrari. "Integrated analysis of microRNAs and mRNAs in myelopoiesis: miR-299-5p role in CD34+ cells commitment". *Cell Death*

Dis. 2010;1:e28. *Macmillan Publishers, part of Springer Nature, London, UK. ISSN 2041-4889. doi: 10.1038/cddis.2010.5. I.F (JCR) 2022: 9*

36. Lemoli RM, Salvestrini V, **Bianchi E**, Bertolini F, Fogli M, Amabile M, Tafuri A, Salati S, Zini R, Testoni N, Rabascio C, Rossi L, Martin-Padura I, Castagnetti F, Marighetti P, Martinelli G, Baccarani M, Ferrari S, Manfredini R. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34⁺ cell population with intrinsic resistance to imatinib. *Blood*. 2009 Dec 10;114(25):5191-200. *The American Society of Hematology, Washington, DC, USA. ISSN 0006-4971. doi: 10.1182/blood-2008-08-176016. I.F (JCR) 2022: 20.3*
37. Cellai C, Laurenzana A, **Bianchi E**, Sdelci S, Manfredini R, Vannucchi AM, Caporale R, Balliu M, Mannelli F, Ferrari S, Bosi A, Miniati D, Cocco PL, Veronneau S, Stankova J, Paoletti F. Mechanistic insight into WEB- 2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. *Exp Hematol*. 2009 Oct;37(10):1176-1185.e21. *Elsevier Inc. Chicago, Illinois, USA. ISSN 0301-472X. doi: 10.1016/j.exphem.2009.07.002. I.F (JCR) 2022: 2.6*
38. Salati S.[°], Zini R.[°], **Bianchi E.**, Testa A., Mavilio F., Manfredini R. and Ferrari Se. "Role of CD34 antigen in myeloid differentiation of human hematopoietic progenitor cells". *Stem Cells*. 2008 Apr;26(4):950-9. *AlphaMed Press, Durham, NC, USA. ISSN 1066-5099. doi: 10.1634/stemcells.2007-0597. I.F (JCR) 2022: 5.2*
39. Salati S.[°], **Bianchi E.**[°], Zini R., Tenedini E., Quaglini D., Manfredini R. and Ferrari Se.. "Eosinophils, but not neutrophils, exhibit an efficient DNA repair machinery and high nucleolar activity". *Haematologica*. 2007 Oct;92(10):1311-8. *Ferrata Storti Foundation, Pavia, Italy. ISSN 0390-6078. doi: 10.3324/haematol.11472. °S.S. and E.B. equally contributed to this study. I.F (JCR) 2022: 10.1*
40. Guglielmelli P, Zini R., Bogani C., Salati S., Pancrazzi A., **Bianchi E.**, Mannelli F., Ferrari Se., Le Bousse-Kerdilès M.C., Bosi A., Barosi G., Migliaccio A.R., Manfredini R., Vannucchi A.M.. "Molecular profiling of CD34⁺ cells in Idiopathic Myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1)". *Stem Cells*. 2007 Jan;25(1):165-73. *AlphaMed Press, Durham, NC, USA. ISSN 1066-5099. doi: : 10.1634/stemcells.2006-0351. I.F (JCR) 2022: 5.2*
41. Tagliafico E., Tenedini E., Ferrari F., Roncaglia E., Bicciato S., Manfredini R., Zini R., Salati S., **Bianchi E.**, Grande A., Gemelli C., Montanari M., Vignudelli T., Zanicco-Marani T., Parenti S., Paolucci P., Martinelli G., Piccaluga P.P., Baccarani M., Specchia G., Torelli U., Ferrari S. "Identification of a molecular signature predictive of refractoriness in Acute Myeloid Leukemia". *Leukemia*. 2006 Oct;20(10):1751-8. Epub 2006 Aug 17. *Macmillan Publishers, part of Springer Nature, London, UK. ISSN 0887-6924. doi: 10.1038/sj.leu.2404358. I.F (JCR) 2022: 11.4*

Modena, 6/8/2026